(Q41752261)

8 October 2017

Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study (English)

1 reference

8 October 2017

1 reference

1 reference

Sivi Ouwerkerk-Mahadevan

10

object named as

Sivi Ouwerkerk-Mahadevan

0 references

Chloe Orkin

3

object named as

Chloe Orkin

1 reference

8 October 2017

Douglas Dieterich

1

1 reference

8 October 2017

Jürgen Kurt Rockstroh

2

1 reference

8 October 2017

Félix Gutiérrez

4

1 reference

8 October 2017

Marina B Klein

5

1 reference

8 October 2017

Jacques Reynes

6

1 reference

8 October 2017

Umesh Shukla

7

1 reference

8 October 2017

Alan Jenkins

8

1 reference

8 October 2017

Oliver Lenz

9

1 reference

8 October 2017

Sivi Ouwerkerk-Mahadevan

10

1 reference

8 October 2017

Monika Peeters

11

1 reference

8 October 2017

Guy De La Rosa

12

1 reference

8 October 2017

Lotke Tambuyzer

13

1 reference

8 October 2017

Wolfgang Jessner

14

1 reference

8 October 2017

language of work or name

English

0 references

publication date

5 September 2014

1 reference

Clinical Infectious Diseases

8 October 2017

1 reference

8 October 2017

59

1 reference

8 October 2017

11

1 reference

8 October 2017

1579-1587

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

8 October 2017

1 reference

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Hepatitis C therapy update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU675

21 January 2018

Identifiers

DOI

10.1093/CID/CIU675

1 reference

8 October 2017

1 reference